Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Bridgewater, John"'
Autor:
Meric-Bernstam, Funda, Bahleda, Rastislav, Hierro, Cinta, Sanson, Marc, Bridgewater, John, Arkenau, Hendrik-Tobias, Tran, Ben, Kelley, Robin Kate, Park, Joon Oh, Javle, Milind, He, Yaohua, Benhadji, Karim A, Goyal, Lipika
Publikováno v:
Cancer discovery, vol 12, iss 2
Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::84f7a4f19c8221a16a0bb628142dcf26
https://escholarship.org/uc/item/4qx9j237
https://escholarship.org/uc/item/4qx9j237
Autor:
Taylor, Stuart A, Mallett, Susan, Miles, Anne, Morris, Stephen, Quinn, Laura, Clarke, Caroline S, Beare, Sandy, Bridgewater, John, Goh, Vicky, Janes, Sam, Koh, Dow-Mu, Morton, Alison, Navani, Neal, Oliver, Alfred, Padhani, Anwar, Punwani, Shonit, Rockall, Andrea, Halligan, Steve
Publikováno v:
Health Technology Assessment, Vol 23, Iss 66 (2019)
Background Whole-body magnetic resonance imaging is advocated as an alternative to standard pathways for staging cancer. Objectives The objectives were to compare diagnostic accuracy, efficiency, patient acceptability, observer variability and cost-e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd341bb5ff98d7e4b4d9440cf5b27339
http://hdl.handle.net/10044/1/77695
http://hdl.handle.net/10044/1/77695
Autor:
Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W, Grp, Adv Biliary Canc Working
Publikováno v:
Lamarca, A, Palmer, D H, Wasan, H S, Ross, P J, Ma, Y T, Arora, A, Falk, S, Gillmore, R, Wadsley, J, Patel, K, Anthoney, A, Maraveyas, A, Iveson, T, Waters, J S, Hobbs, C, Barber, S, Ryder, W D, Ramage, J, Davies, L M, Bridgewater, J A & Valle, J W 2021, ' Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial ', The Lancet Oncology, vol. 22, no. 5, pp. 690-701 . https://doi.org/10.1016/S1470-2045(21)00027-9
LANCET ONCOLOGY
The Lancet. Oncology
LANCET ONCOLOGY
The Lancet. Oncology
Background\ud \ud Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b648e2fdd5880868d388d1b0aac4b6ac
https://linkinghub.elsevier.com/retrieve/pii/S1470204521000279
https://linkinghub.elsevier.com/retrieve/pii/S1470204521000279
Autor:
Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen A., Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S.., Paul, James, Universitat Autònoma de Barcelona
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a772a09ef13048c2095033075e2c97df
http://hdl.handle.net/2072/449826
http://hdl.handle.net/2072/449826
Autor:
Cox, Samantha, Hurt, Christopher, Grenader, Tal, Mukherjee, Somnath, Bridgewater, John, Crosby, Thomas
Publikováno v:
Radiotherapy and Oncology
Background and purpose The derived neutrophil–lymphocyte ratio (dNLR) is a validated prognostic biomarker for cancer survival but has not been extensively studied in locally-advanced oesophageal cancer treated with definitive chemoradiotherapy (dCR
Autor:
Miles, Anne, Taylor, Stuart A, Evans, Ruth EC, Halligan, Steve, Beare, Sandy, Bridgewater, John, Goh, Vicky, Janes, Sam, Navani, Neil, Oliver, Alf, Morton, Alison, Rockall, Andrea, Clarke, Caroline S, Morris, Stephen, STREAMLINE investigators
OBJECTIVES: To determine the importance placed by patients on attributes associated with whole-body MRI (WB-MRI) and standard cancer staging pathways and ascertain drivers of preference. METHODS: Patients recruited to two multi-centre diagnostic accu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______109::ac8e60e3e5add073a475641fee5522da
https://www.repository.cam.ac.uk/handle/1810/302727
https://www.repository.cam.ac.uk/handle/1810/302727
Autor:
Miles, Anne, Taylor, Stuart A., Evans, Ruth E. C., Halligan, Steve, Beare, Sandy, Bridgewater, John, Goh, Vicky, Janes, Sam, Navani, Neil, Oliver, Alf, Morton, Alison, Rockall, Andrea, Clarke, Caroline S., Morris, Stephen
Publikováno v:
Miles, A, Taylor, S A, Evans, R E C, Halligan, S, Beare, S, Bridgewater, J, Goh, V, Janes, S, Navani, N, Oliver, A, Morton, A, Rockall, A & Clarke, C S & Morris, S 2019, ' Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer : a discrete choice experiment ', European Radiology, vol. 29, no. 7, pp. 3889-3900 . https://doi.org/10.1007/s00330-019-06153-4
European Radiology
European Radiology
Objectives To determine the importance placed by patients on attributes associated with whole-body MRI (WB-MRI) and standard cancer staging pathways and ascertain drivers of preference. Methods Patients recruited to two multi-centre diagnostic accura
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::98b45c8c979f24c023795617bbbbfa02
https://kclpure.kcl.ac.uk/ws/files/111620332/Patient_preferences_for_whole_MILES_Accepted_11_March_2019_GOLD_VoR_CC_BY_.pdf
https://kclpure.kcl.ac.uk/ws/files/111620332/Patient_preferences_for_whole_MILES_Accepted_11_March_2019_GOLD_VoR_CC_BY_.pdf
Autor:
Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengy, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., Paul, James
Publikováno v:
Iveson, T J, Kerr, R S, Saunders, M P, Cassidy, J, Hollander, N H, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K A, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A S, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R K, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H S & Paul, J 2018, ' 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial ', Lancet Oncology, vol. 19, no. 4, pp. 562-578 . https://doi.org/10.1016/S1470-2045(18)30093-7
Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2d57e07e4b86c46d7bdc8853680f2d02
https://doi.org/10.1016/s1470-2045(18)30093-7
https://doi.org/10.1016/s1470-2045(18)30093-7
Autor:
Bridgewater, John, Lopes, Andre, Beare, Sandra, Duggan, Marian, Lee, Dymphna, Ricamara, Maravic, McEntee, Delyth, Sukumaran, Ajithkumar, Wasan, Harpreet, Valle, Juan W.
Publikováno v:
BMC Cancer
Bridgewater, J, Lopes, A, Beare, S, Duggan, M, Lee, D, Ricamara, M, McEntee, D, Sukumaran, A, Wasan, H & Valle, J W 2016, ' A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer : the ABC-04 study ', BMC Cancer, vol. 16, no. 369 . https://doi.org/10.1186/s12885-016-2174-8
Bridgewater, J, Lopes, A, Beare, S, Duggan, M, Lee, D, Ricamara, M, McEntee, D, Sukumaran, A, Wasan, H & Valle, J W 2016, ' A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer : the ABC-04 study ', BMC Cancer, vol. 16, no. 369 . https://doi.org/10.1186/s12885-016-2174-8
Background Combined treatment with cisplatin and gemcitabine (CisGem) is the standard of care for patients with advanced biliary tract cancer (ABC). Selumetinib (AZD6244, ARRY-142886) potently and selectively inhibits MEK1/2, an intracellular kinase
Autor:
André, Thierry, Boni, Corrado, Mounedji-Boudiaf, Lamia, Navarro, Matilde, Tabernero Caturla, Josep, Hickish, Tamas, Topham, Clare, Zaninelli, Marta, Clingan, Philip, Bridgewater, John, Tabah-Fisch, Isabelle, Gramont, Aimery de, Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Background: The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus